Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMIMK84)

• Drug Name: D2C7 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Glioblastoma of brain	2A00.00	Phase 1	[1]

• Cross-matching ID: TTD Drug ID: DMIMK84

Molecule-Related Drug Atlas

Drug(s) Targeting Epidermal growth factor receptor (EGFR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sorafenib	DMS8IFC	Adenocarcinoma	2D40	Approved	[3]
Lapatinib	DM3BH1Y	Breast cancer	2C60-2C65	Approved	[4]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[5]
Erlotinib	DMCMBHA	Adrenal gland neoplasm		Approved	[6]
Vandetanib	DMRICNP	Solid tumour/cancer	2A00-2F9Z	Approved	[7]
Dacomitinib	DMOH8VY	Non-small-cell lung cancer	2C25.Y	Approved	[8]
BIBW 2992	DMTKD7Q	Non-small-cell lung cancer	2C25.Y	Approved	[9]
SKI-758	DMQ8E9R	Ischemia	8B10-8B11	Approved	[10]
Epidermal growth factor	DMVONE6	Vulnerary	ND56.Z	Approved	[8]
Merimepodib	DM0HS92	Breast cancer	2C60-2C65	Approved	[11]

Drug(s) Targeting Epidermal growth factor receptor variant III (EGFR vIII)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Anti-EGFRvIII CAR transduced PBL	DMDKTYU	Brain cancer	2A00	Phase 1/2	[12]
EGFRvIII CAR	DMC284G	Glioblastoma multiforme	2A00.0	Phase 1/2	[13]
Anti-EGFR V III CAR-T cells	DM8EAGV	Glioma	2A00.0	Phase 1/2	[14]
AMG 596	DM4G1SP	Glioblastoma multiforme	2A00.0	Phase 1	[15]
EGFRvIII CAR T cells	DM6XWV4	Glioblastoma multiforme	2A00.0	Phase 1	[16]
CAR-T cells targeting EGFRviii	DMRSG04	Glioblastoma multiforme	2A00.0	Phase 1	[17]
Anti-EGFRvIII CAR T cells	DM73920	Glioblastoma multiforme	2A00.0	Phase 1	[18]
CART-EGFRvIII T cells	DMGPR1C	Recurrent glioblastoma	2A00.00	Phase 1	[19]
EGFRvIII-CARs	DMA46RN	Recurrent glioblastoma	2A00.00	Phase 1	[20]
CAR-T cells targeting EGFRviii	DMRSG04	Glioblastoma multiforme	2A00.0	Phase 1	[21]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Epidermal growth factor receptor (EGFR)	TTGKNB4	EGFR_HUMAN	Not Available	[2]
Epidermal growth factor receptor variant III (EGFR vIII)	TTZ6B2I	EGFR_HUMAN	Not Available	[2]

References

• [1] ClinicalTrials.gov (NCT02303678) D2C7 for Adult Patients With Recurrent Malignant Glioma. U.S. National Institutes of Health.
• [2] Improved efficacy against malignant brain tumors with EGFRwt/EGFRvIII targeting immunotoxin and checkpoint inhibitor combinations. J Immunother Cancer. 2019 May 29;7(1):142.
• [3] Nasopharyngeal carcinoma: Current treatment options and future directions. J Nasopharyng Carcinoma, 2014, 1(16): e16.
• [4] Triple negative breast cancer--current status and prospective targeted treatment based on HER1 (EGFR), TOP2A and C-MYC gene assessment. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2009 Mar;153(1):13-7.
• [5] Gefitinib ('Iressa', ZD1839) and new epidermal growth factor receptor inhibitors. Br J Cancer. 2004 Feb 9;90(3):566-72.
• [6] Quantitative prediction of fold resistance for inhibitors of EGFR. Biochemistry. 2009 Sep 8;48(35):8435-48.
• [7] A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
• [8] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1797).
• [9] Boehringer Ingelheim. Product Development Pipeline. June 2 2009.
• [10] Synthesis and Src kinase inhibitory activity of a series of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-7-furyl-3-quinolinecarbonitriles. J Med Chem. 2006 Dec 28;49(26):7868-76.
• [11] Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
• [12] ClinicalTrials.gov (NCT01454596) CAR T Cell Receptor Immunotherapy Targeting EGFRvIII for Patients With Malignant Gliomas Expressing EGFRvIII. U.S. National Institutes of Health.
• [13] EGFRvIII mCAR-modified T-cell therapy cures mice with established intracerebral glioma and generates host immunity against tumor-antigen loss. Clin Cancer Res. 2014 Feb 15;20(4):972-84.
• [14] ClinicalTrials.gov (NCT03638206) Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies
• [15] Clinical pipeline report, company report or official report of Amgen.
• [16] ClinicalTrials.gov (NCT02664363) EGFRvIII CAR T Cells for Newly-Diagnosed WHO Grade IV Malignant Glioma
• [17] ClinicalTrials.gov (NCT03170141) Immunogene-modified T (IgT) Cells Against Glioblastoma Multiforme
• [18] ClinicalTrials.gov (NCT02844062) Pilot Study of Autologous Anti-EGFRvIII CAR T Cells in Recurrent Glioblastoma Multiforme
• [19] ClinicalTrials.gov (NCT02209376) Autologous T Cells Redirected to EGFRVIII-With a Chimeric Antigen Receptor in Patients With EGFRVIII+ Glioblastoma
• [20] ClinicalTrials.gov (NCT03283631) Intracerebral EGFR-vIII CAR-T Cells for Recurrent GBM
• [21] ClinicalTrials.gov (NCT03267173) Evaluate the Safety and Efficacy of CAR-T in the Treatment of Pancreatic Cancer.